Each piece of chewing gum contains 40 mg resveratrol.
Resveratrol supplier Fluxome (Easton, PA) announced that its ingredient is now part of a chewing gum called Heart Strong Gum, from Cheiron Holdings. As its name indicates, the product is touted for cardiovascular benefits, including reducing inflammation of the heart, according to Cheiron.
Each piece of chewing gum contains 40 mg resveratrol, which the Cheiron says is equivalent to 40 glasses of red wine.
Moreover, the brand touts chewing gum as a more bioavailable delivery system over pills. According to the company, with pills much of an active ingredient like resveratrol may not reach the bloodstream or can be quickly metabolized by the digestive tract and liver. By contrast, it says on its website, “The resveratrol in the gum is absorbed directly into [the] bloodstream [through] glands under [the] tongue (just like nicotine gum or caffeine gum). This skips the effects of the digestive track, allowing a greater percentage of resveratrol to enter [the] bloodstream and stay there for a longer period of time.” To maintain resveratrol levels in the blood, the company recommends chewing a piece of gum “every few hours.”
“We are pleased to work with Cheiron to bring this unique resveratrol product to consumers,” said Angela Tsetsis, president and CEO of Fluxome, in a press release. “Heart Strong Gum with Fluxome resveratrol is an easy way for everyone to get the health benefits of resveratrol.” Fluxome’s resveratrol is described as a natural and pure source of >98% trans-resveratrol.
“The quality and consistency of Fluxome resveratrol is unbeatable,” stated Griff Causey, cofounder of Cheiron Holdings. “It provides a 98% pure resveratrol that is tasteless, odorless, and mixes perfectly into Heart Strong Gum.”
“Our customers get all the benefits of resveratrol with nothing but a minty fresh taste,” Causey added.
Yili to pilot Xampla’s microscopic natural biopolymer capsules for nutrient fortification
July 17th 2024Xampla, a manufacturer natural biopolymers, has announced a partnership with Yili Innovation Centre Europe to test and validate Xampla’s microscopic natural biopolymer capsules used to fortify a range of products with vitamins and nutrients.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.